Trial Profile
A Phase III Study Of Daunorubicin And Cytarabine +/- G3139 (Genesense, Oblimersen Sodium, NSC 683428, IND 58842), A BCL2 Antisense Oligodeoxynucleotide, In Previously Untreated Patients With Acute Myeloid Leukemia (AML) aged greater than or equal to 60 Years.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results evaluating event-free survival (EFS) as a surrogate endpoint for OS in untreated AML from 4 multicenter, randomized controlled phase III trials (n=2475), NCT00085124, NCT00651261,NCT00085709, NCT00049517, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 19 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Apr 2011 Status changed from completed to active, no longer recruiting, according to ClinicalTrials.gov..